March 11, 2025 - 03:42
BOSTON & MONTREAL, March 10, 2025 -- enGene Holdings Inc., a clinical-stage company specializing in non-viral genetic medicines, has reported its financial results for the first quarter ending January 31, 2025. The company is focused on advancing innovative therapies aimed at treating various diseases through its proprietary genetic medicine platform.
In the financial report, enGene highlighted key metrics that reflect its ongoing commitment to research and development in the genetic medicine field. The company continues to invest in its pipeline of product candidates, which are designed to address unmet medical needs. The management team expressed optimism about the progress made during the quarter and reaffirmed its strategic goals moving forward.
Additionally, enGene provided insights into its operational achievements and future plans. The company remains dedicated to enhancing its capabilities and expanding its footprint in the genetic medicine landscape, aiming to deliver transformative solutions to patients worldwide.
